Time-to-treatmentPercutaneous coronary interventionInternational guidelines for the management of patients with ST-elevation myocardial infarction (STEMI) recommend various performance measures to monitor the quality of STEMI systems of care. Door-to-balloon (D2B) time (arrival at hospital to percutaneous ...
治疗失败时间 time to treatment failure,TTF 定义为:由随机化开始至「退出试验」,退出原因可能是患者拒绝、疾病进展、患者死亡、不良事件等。 由于不单单展现药物疗效,因而不建议用于疗效确认性试验。 TTF 的本质是一具有综合特性的指标,所以,可造成为了达到毒性的降低,而潜在影响了预期疗效的产生。
Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI Despite the widespread use of electrocardiographic changes to characterize patients presenting with acute myocardial infarction, little is known about rece... DD Mcmanus,JM Gore,JL Yarzebski,... - 《American ...
This cohort study of patients with breast, prostate, non-small cell lung, and colon cancer assesses the association of time from diagnosis to treatment
To the best of our knowledge, there are no studies evaluating the influence of the unit of the first contact on the frequency and time of pharmacological treatment during an acute coronary syndrome (ACS) event. The main objective was to investigate if the unit of first contact influenced the ...
Time to reperfusion and treatment effect for acute ischemic stroke. JAMA Neurol. 2016;73(2):190-196.PubMedGoogle ScholarCrossref 11. Menon BK, Sajobi TT, Zhang Y, et al. Analysis of workflow and time to treatment on thrombectomy outcome in the Endovascular Treatment for Small Core and ...
A total of 2559 patients were included; median onset-to-treatment-initiation time was 8.3 h (IQR:5.8-11.0). Comparing DAPT to aspirin, the rate of disability attributed to the index event at 90-day follow-up was 5.1 % vs. 8.6 % (OR 0.57; 95 % CI:0.33-0.99) in patients treated <...
Importance Randomized clinical trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent. However, modest sample sizes have limited characterization of the extent to which onset to treatment (OTT) time influences outcome; and the general...
1:37 | In terms of results, we found that frontline daratumumab, lenalidomide, and dexamethasone were associated with a longer time-to-next-treatment or death. It had a 42% lower likelihood of progressing to another therapy or dying, and the median time-to-next-treatment was 38 months with...
time to treatment;pharyngeal cancer;overall survival;delayed diagnosis 1. Introduction Head and neck cancer (HNC) incidence is increasing worldwide, and the risk factors are usually tobacco smoking, alcohol consumption, Human Papillomavirus (HPV), especially types 16 and 18, and infection with Epstein...